Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (12165)	9/7/2005 6:44:47 PM
From: rrufff	Read Replies (2) \| Respond to of 37387

Re CTE - an old summary from their IR person. Best to Stay with the Facts by: daveaurelius 09/23/04 11:00 am Msg: 12341 of 12350 Though it is not my habit, nor the habit of my firm to post on message boards; so consider this an exception to the rule. It is important that I make clear that neither I nor the Aurelius Consulting Group has received one share of stock or options from CardioTech (CTE; We nor I have ever received one share of CTE stock as compensation. I repeat, never. We are paid on a monthly cash basis. If you read the disclosure on our CTE profile you will see that is precisely the case. To suggest otherwise is dishonest. It always better to stay with the facts. These are the facts: 1)CTE is fundamentally in superb conditions: 0 debt; $5.6 million in cash; is cash flow positive and reported a profitable 2nd quarter. 2)CTE's Coronary Artery Bypass Graft (CABG)is working. CTE has one patient who has lived a year and two more coming up on a year. 3) The CABG represents a $1 billion + opportunity and CTE is the only company in the world in human clinical trial with what is considered the holy grail of medical devices. 4)CTE is trading only 2.5 x revenues ($21.7 million) in a sector that trades at 4-8 x revenues (See CDIC or ABMD) At 5 x revenues CTE would trade at $6.00 5)The slide in the stock is a temporary aberration; at the end of the day, CTE will trade at a fair mutiple. 6) The Company is expecting revenue growth at minimum of 20-25% for fiscal 05, and expects to remain cash-flow positive. 7) The Company has several exciting technologies that are in the early stage of commercialization: i.e. wound dressings, a line of facial masks, coated oxygenators and blood filters... 8) In additon to the CABG, CTE has established a joint venture to develop both a bare metal stent and a drug-eluting stent. 9) The Gish acqusition was accretive to earnings. Gish has developed a coating for their products and has entered a $200 million market. 10) CTE is a very well managed company; proof is in the pudding; See their balance sheet. 11) Dr. Michael Szycher, CEO of CTE, is world authority on polyurethanes, one of the inventors of the artificial heart, the HeartMate, former co-founder and co-chairman of PLMD (a $30 + Nasdaq stock) and has a long history of success. 12) In sum, CTE has superb fundamentals, a strong cash position, 0 debt, is cash flow positive; with new products in the pipeline, including the CABG which addresses a $1 billion + market.